Ann Weinacker

Pulmonologist, Critical care specialist

Professor of Medicine (Pulmonary and Critical Care) at the Stanford University Medical Center
Ann Weinacker is the current Immediate Past Chief of Staff at SHC. She was elected Vice Chief of Staff in 2010 and became Chief of Staff in 2011. Dr. Weinacker has extensive experience in SHC clinical and administrative leadership, in addition to serving since 1999 as a fulltime faculty member in the Stanford University School of Medicine. She is currently Professor of Medicine, Division of Pulmonary and Critical Care Medicine; Associate Director of the Intensive Care Unit; director of the Critical Care Medicine Fellowship Program; and Vice Chair of Medicine for Quality Implementation. A strong advocate for patient centricity, Dr. Weinacker was appointed in November 2009 to be one of four leaders designated to actively design, guide and implement strategies to improve the patient experience at Stanford. Her research focus is ICU outcomes.

Weinacker began her career as a nurse and nurse anesthetist before completing her M.D. at the University of South Alabama College of Medicine, Mobile, in 1986. Her advanced training includes a pulmonary and critical care fellowship and a cardiovascular postdoctoral research fellowship, completed at the University of California, San Francisco in 1994. She is the winner of numerous national honors, editorial posts. Locally, she received the SHC Board of Hospital Director’s coveted Denise O’Leary Award for Clinical Excellence in 2008.

Chest Clinic

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-725-7061
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: University of South Alabama Medical Center (1990) AL

Internship: University of South Alabama Medical Center (1987) AL

Board Certification: Critical Care Medicine, American Board of Internal Medicine (1993)

Board Certification: Pulmonary Disease, American Board of Internal Medicine (1992)

Fellowship: UCSF Medical Center (1994) CA

Board Certification: Internal Medicine, American Board of Internal Medicine (1989)

Medical Education: University of South Alabama Medical Center (1986) AL

M.D., University of South Alabama, Medicine (1986)

R.N. Anesthetist, University of South Alabama, Anesthesia (1980)

Honors & Awards

Denise O'Leary Award for Clinical Excellence, Stanford Hospital and Clinics Board of Directors (2008)

Honor Medical Society, Alpha Omega Alpha (2006)

Excellence in Teaching, Stanford University School of Medicine (2004)

Chief Residents' Teaching Award, Stanford School of Medicine (2003)

Leadership Development in Pulmonary & Critical Care Medicine, American College of Chest Physicians (1999)

Victor Benator Award for Best Teaching Resident, University of South Alabama (1989)

Best Intern Award, University of South Alabama (1987)

Award for Service to Medical School, University of South Alabama College of Medicine (1986)

Administrative Appointments

Fellowship Director, Critical Care Medicine, Department of Medicine, Stanford University (2014 - Present)

Vice Chair, Quality -- Implementation, Department of Medicine, Stanford University (2014 - Present)

Continuing Quality Improvement in the ICU Committee, Stanford University School of Medicine (2003 - Present)

Associate Director, Intensive Care Unit, Stanford University Medical Center (1999 - Present)

Chief of Staff, Stanford Hospital and Clinics (2011 - 2014)

Vice Chief of Staff, Stanford Hospital and Clinics (2010 - 2011)

Chair, Emergency Medical Response Team Committee, Stanford University Medical Center (2007 - 2011)

Dean's Task Force for Clinical Excellence, Stanford University School of Medicine (2007 - 2008)

Quality Improvement & Patient Safety Committee, Stanford University Medical Center (2007 - 2008)

Vice Chair, Clinical Affairs, Department of Medicine, Stanford University (2007 - 2008)

Chair, Rapid Response Team Committee, Stanford University Medical Center (2005 - 2007)

Interim Director, Heart-Lung and Lung Transplant Program, Stanford University School of Medicine (2005 - 2006)

Fellowship Director, Pulmonary & Critical Care Medicine, Department of Medicine, Stanford University (2001 - 2002)

Credentials Committee, American College of Chest Physicians (2000 - 2004)

Genetic Variation in the Prostaglandin E-2 Pathway Is Associated with Primary Graft Dysfunction
Diamond, J. M., Akimova, T., Kazi, A., Shah, R. J., Cantu, E., & Christie, J. D. (2014). Genetic Variation in the Prostaglandin E-2 Pathway Is Associated with Primary Graft Dysfunction. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 189(5), 567-575.

Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation
Shah, R. J., Wickersham, N., Lederer, D. J., Palmer, S. M., Cantu, E., & Ware, L. B. (2014). Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION, 14(2), 446-452.

Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.
Shah, R. J., Diamond, J. M., Cantu, E., Lee, J. C., Lederer, D. J., & Christie, J. D. (2013). Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation. Chest, 144(2), 616-622.

Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
Diamond, J. M., Lee, J. C., Kawut, S. M., Shah, R. J., Localio, A. R., & Christie, J. D. (2013). Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 187(5), 527-534.

Still a man's world, but why?
Weinacker, A., & Stapleton, R. D. (2013). Still a man's world, but why?. Critical care (London, England), 17(1), 113.

Elevated Plasma Angiopoietin-2 Levels and Primary Graft Dysfunction after Lung Transplantation
Diamond, J. M., Porteous, M. K., Cantu, E., Meyer, N. J., Shah, R. J., & Christie, J. D. (2012). Elevated Plasma Angiopoietin-2 Levels and Primary Graft Dysfunction after Lung Transplantation. PLOS ONE, 7(12).

Variation in PTX3 Is Associated with Primary Graft Dysfunction after Lung Transplantation
Diamond, J. M., Meyer, N. J., Feng, R., Rushefski, M., Lederer, D. J., & Christie, J. D. (2012). Variation in PTX3 Is Associated with Primary Graft Dysfunction after Lung Transplantation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 186(6), 546-552.

A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation
Shah, R. J., Bellamy, S. L., Localio, A. R., Wickersham, N., Diamond, J. M., & Christie, J. D. (2012). A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(9), 942-949.

High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study
Pickham, D., Helfenbein, E., Shinn, J. A., Chan, G., Funk, M., & Drew, B. J. (2012). High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study. CRITICAL CARE MEDICINE, 40(2), 394-399.

Obesity and Primary Graft Dysfunction after Lung Transplantation The Lung Transplant Outcomes Group Obesity Study
Lederer, D. J., Kawut, S. M., Wickersham, N., Winterbottom, C., Bhorade, S., & Christie, J. D. (2011). Obesity and Primary Graft Dysfunction after Lung Transplantation The Lung Transplant Outcomes Group Obesity Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 184(9), 1055-1061.

Elevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis
Diamond, J. M., Lederer, D. J., Kawut, S. M., Lee, J., Ahya, V. N., & Christie, J. D. (2011). Elevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis. AMERICAN JOURNAL OF TRANSPLANTATION, 11(11), 2517-2522.

Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis
Sims, M. W., Beers, M. F., Ahya, V. N., Kawut, S. M., Sims, K. D., & Ware, L. B. (2011). Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. CHEST, 140(2), 489-496.

Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis
Fang, A., Studer, S., Kawut, S. M., Ahya, V. N., Lee, J., & Christie, J. D. (2011). Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. CHEST, 139(4), 782-787.

Elevated Plasma Clara Cell Secretory Protein Concentration Is Associated with High-Grade Primary Graft Dysfunction
Diamond, J. M., Kawut, S. M., Lederer, D. J., Ahya, V. N., Kohl, B., & Ware, L. B. (2011). Elevated Plasma Clara Cell Secretory Protein Concentration Is Associated with High-Grade Primary Graft Dysfunction. AMERICAN JOURNAL OF TRANSPLANTATION, 11(3), 561-567.

The "Slow Code" Should Be a "No Code"
Weinacker, A. (2011). The "Slow Code" Should Be a "No Code". AMERICAN JOURNAL OF BIOETHICS, 11(11), 27-29.

Construct validity of the definition of primary graft dysfunction after lung transplantation
Christie, J. D., Bellamy, S., Ware, L. B., Lederer, D., Hadjiliadis, D., & Kawut, S. M. (2010). Construct validity of the definition of primary graft dysfunction after lung transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 29(11), 1231-1239.

Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction
Christie, J. D., Shah, C. V., Kawut, S. M., Mangalmurti, N., Lederer, D. J., & Ware, L. B. (2009). Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 180(10), 1010-1015.

Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation
Kawut, S. M., Okun, J., Shimbo, D., Lederer, D. J., De Andrade, J., & Christie, J. D. (2009). Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. CHEST, 136(1), 237-244.

Plasma Cytokines and Chemokines in Primary Graft Dysfunction Post-Lung Transplantation
Hoffman, S. A., Wang, L., Shah, C. V., Ahya, V. N., Pochettino, A., & Christie, J. D. (2009). Plasma Cytokines and Chemokines in Primary Graft Dysfunction Post-Lung Transplantation. AMERICAN JOURNAL OF TRANSPLANTATION, 9(2), 389-396.

Randomized clinical trial of activated protein C for the treatment of acute lung injury
Liu, K. D., Levitt, J., Zhuo, H., Kallet, R. H., Brady, S., & Matthay, M. A. (2008). Randomized clinical trial of activated protein C for the treatment of acute lung injury. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 178(6), 618-623.

Plasma intercellular adhesion molecule-1 and von willebrand factor in primary graft dysfunction after lung transplantation
Covarrubias, M., Ware, L. B., Kawut, S. M., de Andrade, J., Milstone, A., & Christie, J. D. (2007). Plasma intercellular adhesion molecule-1 and von willebrand factor in primary graft dysfunction after lung transplantation. AMERICAN JOURNAL OF TRANSPLANTATION, 7(11), 2573-2578.

Management strategies for patients with pulmonary hypertension in the intensive care unit
Zamanian, R. T., Haddad, F., Doyle, R. L., & Weinacker, A. B. (2007). Management strategies for patients with pulmonary hypertension in the intensive care unit. CRITICAL CARE MEDICINE, 35(9), 2037-2050.

Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction
Christie, J. D., Robinson, N., Ware, L. B., Plotnick, M., De Andrade, J., & Kawut, S. M. (2007). Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 175(1), 69-74.

Smoking in movies
Glantz, S. A., & Polansky, J. (2006). Smoking in movies. CHEST, 129(2), 495-495.

High dose cyclophosphamide efficacy in a patient with refractory anti-MuSK positive myasthenia gravis
Lin P, Martin B, Weinacker A, & So Y. (2006). High dose cyclophosphamide efficacy in a patient with refractory anti-MuSK positive myasthenia gravis. Muscle & Nerve, 33.

Smoking in contemporary American cinema
Omidvari, K., Lessnau, K., Kim, J., Mercante, D., Weinacker, A., & Mason, C. (2005). Smoking in contemporary American cinema. CHEST, 128(2), 746-754.

The value of preoperative pulmonary rehabilitation.
Takaoka, S. T., & Weinacker, A. B. (2005). The value of preoperative pulmonary rehabilitation. Thoracic surgery clinics, 15(2), 203-211.

Lung transplantation: A decade of experience
Moffatt SD, Demers P, Robbins RC, Doyle R, Weinacker A, & Whyte RI. (2005). Lung transplantation: A decade of experience. J Heart Lung Transplant, 24.

Intensive care unit support of hematopoietic stem cell transplant recipients: A case for cautious optimism
Weinacker, A. (2003). Intensive care unit support of hematopoietic stem cell transplant recipients: A case for cautious optimism. CRITICAL CARE MEDICINE, 31(6), 1873-1875.

Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia
Fowler, R. A., Flavin, K. E., Barr, J., Weinacker, A. B., Parsonnet, J., & Gould, M. K. (2003). Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. CHEST, 123(3), 835-844.

Blood cultures in the critical care unit - Improving utilization and yield
Shafazand, S., & Weinacker, A. B. (2002). Blood cultures in the critical care unit - Improving utilization and yield. CHEST, 122(5), 1727-1736.

Ethical issues in the long term management of progressive degenerative neuromuscular diseases
Vaszar, L. T., Weinacker, A. B., Henig, N. R., & Raffin, T. A. (2002). Ethical issues in the long term management of progressive degenerative neuromuscular diseases. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 23(3), 307-314.

Nodular invasive tracheobronchitis due to Aspergillus in a patient with systemic lupus erythematosus
Angelotti, T., Krishna, G., Scott, J., Berry, G., & Weinacker, A. (2002). Nodular invasive tracheobronchitis due to Aspergillus in a patient with systemic lupus erythematosus. LUPUS, 11(5), 325-328.

A cystic upper lobe lesion in a healthy nonsmoking man - Angiosarcoma of the left upper lobe, presumed metastatic
Leonard, C. T., Weinacker, A., Berry, G., & Whyte, R. I. (2001). A cystic upper lobe lesion in a healthy nonsmoking man - Angiosarcoma of the left upper lobe, presumed metastatic. CHEST, 120(5), 1725-1727.

Diagnostic yield of screening colonoscopies in lung transplant candidates
Singer, L. G., Weinacker, A. B., Levin, L., Doyle, R. L., & Theodore, J. (2001). Diagnostic yield of screening colonoscopies in lung transplant candidates. TRANSPLANTATION, 72(3), 530-532.

Acute respiratory distress syndrome: Physiology and new management strategies
Weinacker, A. B., & Vaszar, L. T. (2001). Acute respiratory distress syndrome: Physiology and new management strategies. ANNUAL REVIEW OF MEDICINE, 52, 221-237.

A brave new world: Remote intensive care unit care for the 21st century
Shafazand, S., Shigemitsu, H., & Weinacker, A. B. (2000). A brave new world: Remote intensive care unit care for the 21st century. CRITICAL CARE MEDICINE, 28(12), 3945-3946.

Withdrawing life support from the critically ill
McGee, D. C., Weinacker, A. B., & Raffin, T. A. (2000). Withdrawing life support from the critically ill. CHEST, 118(5), 1238-1239.

The patient's response to medical futility
McGee, D. C., Weinacker, A. B., & Raffin, T. A. (2000). The patient's response to medical futility. ARCHIVES OF INTERNAL MEDICINE, 160(11), 1565-1566.

Inhalational anthrax - Epidemiology, diagnosis, and management
Shafazand, S., Doyle, R., Ruoss, S., Weinacker, A., & Raffin, T. A. (1999). Inhalational anthrax - Epidemiology, diagnosis, and management. CHEST, 116(5), 1369-1376.

Quality of life and lung volume reduction surgery.
Faul, J. L., Doyle, R. L., Weinacker, A. B., & Raffin, T. A. (1999). Quality of life and lung volume reduction surgery. American journal of critical care , 8(6), 359-360.

beta-adrenergic-blocking agents in bronchospastic diseases: A therapeutic dilemma
Tafreshi, M. J., & Weinacker, A. B. (1999). beta-adrenergic-blocking agents in bronchospastic diseases: A therapeutic dilemma. PHARMACOTHERAPY, 19(8), 974-978.

Systematic reviews and evidence-based critical care medicine: A step in the right direction
Gould, M. K., Leonard, C. T., Weinacker, A. B., & Raffin, T. A. (1998). Systematic reviews and evidence-based critical care medicine: A step in the right direction. AMERICAN JOURNAL OF MEDICINE, 105(6), 551-553.

The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
Schwarzenberger, P., Harrison, L., Weinacker, A., Marrogi, A., Byrne, P., & Kolls, J. K. (1998). The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study. HUMAN GENE THERAPY, 9(17), 2641-2649.

Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma
Schwarzenberger, P., Lei, D. H., Freeman, S. M., Ye, P., Weinacker, A., & Kolls, J. K. (1998). Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 19(2), 333-337.

Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
Schwarzenberger, P., Harrison, L., Weinacker, A., Gaumer, R., Theodossiou, C., & Kolls, J. (1998). Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. journal of the Louisiana State Medical Society , 150(4), 168-174.

DISTRIBUTION OF INTEGRINS ALPHA-V-BETA-6 AND ALPHA-9-BETA-1 AND THEIR KNOWN LIGANDS, FIBRONECTIN AND TENASCIN, IN HUMAN AIRWAYS
Weinacker, A., Ferrando, R., Elliott, M., Hogg, J., Balmes, J., & Sheppard, D. (1995). DISTRIBUTION OF INTEGRINS ALPHA-V-BETA-6 AND ALPHA-9-BETA-1 AND THEIR KNOWN LIGANDS, FIBRONECTIN AND TENASCIN, IN HUMAN AIRWAYS. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 12(5), 547-556.

ROLE OF THE INTEGRIN ALPHA-V-BETA-6 IN CELL ATTACHMENT TO FIBRONECTIN - HETEROLOGOUS EXPRESSION OF INTACT AND SECRETED FORMS OF THE RECEPTOR
Weinacker, A., Chen, A., Agrez, M., CONE, R. I., Nishimura, S., & Sheppard, D. (1994). ROLE OF THE INTEGRIN ALPHA-V-BETA-6 IN CELL ATTACHMENT TO FIBRONECTIN - HETEROLOGOUS EXPRESSION OF INTACT AND SECRETED FORMS OF THE RECEPTOR. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(9), 6940-6948.

IDIOPATHIC GIANT BULLOUS EMPHYSEMA (VANISHING LUNG SYNDROME) - IMAGING FINDINGS IN 9 PATIENTS
Stern, E. J., Webb, W. R., Weinacker, A., & Muller, N. L. (1994). IDIOPATHIC GIANT BULLOUS EMPHYSEMA (VANISHING LUNG SYNDROME) - IMAGING FINDINGS IN 9 PATIENTS. AMERICAN JOURNAL OF ROENTGENOLOGY, 162(2), 279-282.

EFFECTS OF BETA-SUBUNIT CYTOPLASMIC DOMAIN DELETIONS ON THE RECRUITMENT OF THE INTEGRIN ALPHA-NU-BETA-6 TO FOCAL CONTACTS
CONE, R. I., Weinacker, A., Chen, A., & Sheppard, D. (1994). EFFECTS OF BETA-SUBUNIT CYTOPLASMIC DOMAIN DELETIONS ON THE RECRUITMENT OF THE INTEGRIN ALPHA-NU-BETA-6 TO FOCAL CONTACTS. CELL ADHESION AND COMMUNICATION, 2(2), 101-113.

UPPER AND MIDDLE LOBE BRONCHOALVEOLAR LAVAGE TO DIAGNOSE PNEUMOCYSTIS-CARINII PNEUMONIA
Yung, R. C., Weinacker, A. B., Steiger, D. J., Miller, T. R., Stern, E. J., & Golden, J. A. (1993). UPPER AND MIDDLE LOBE BRONCHOALVEOLAR LAVAGE TO DIAGNOSE PNEUMOCYSTIS-CARINII PNEUMONIA. AMERICAN REVIEW OF RESPIRATORY DISEASE, 148(6), 1563-1566.